RTTNews | Dec 20, 2021 04:36PM EST

16:36 Monday, December 20, 2021 (RTTNews) - Pfizer's VYNDAQEL Reduced Risk Of All-Cause Mortality By 41% Among Patients With Transthyretin Amyloid Cardiomyopathy

For comments and feedback: contact editorial@rttnews.comCopyright(c) 2021 RTTNews.com. All Rights Reserved